General Information of Drug (ID: DM056JD)

Drug Name
PF-06648671 Drug Info
Synonyms
1587727-31-8; 2-[(1S)-1-[(2S,5R)-5-[4-Chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydro-2-furanyl]ethyl]-3,4-dihydro-7-(4-methyl-1H-imidazol-1-yl)-2H-pyrido[1,2-a]pyrazine-1,6-dione; CHEMBL3951810; SCHEMBL15611304; BDBM193081; HY-120789; CS-0079177; US9193726, 69; Q29213634; 2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]oxolan-2-yl]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 1 [1]
Cross-matching ID
PubChem CID
73441910
TTD Drug ID
DM056JD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Gamma-secretase (GS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nirogacestat DMUP5Z0 Desmoid tumour 2F7C Approved [3]
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [4]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [5]
Semagacestat DML83IW Parkinson disease 8A00.0 Phase 3 [6]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [4]
MK-0752 DMLTAES Alzheimer disease 8A20 Phase 2 [7]
BMS-708163 DM51LTG Alzheimer disease 8A20 Phase 2 [8]
CHF-5074 DMTE071 Alzheimer disease 8A20 Phase 2 [9]
RO-4929097 DMXA6B3 Breast cancer 2C60-2C65 Phase 2 [10]
AL102 DMCTWIB Desmoid tumour 2F7C Phase 2 [11]
Nirogacestat DMUP5Z0 Desmoid tumour 2F7C Approved [3]
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [4]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [5]
Semagacestat DML83IW Parkinson disease 8A00.0 Phase 3 [6]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [4]
MK-0752 DMLTAES Alzheimer disease 8A20 Phase 2 [7]
BMS-708163 DM51LTG Alzheimer disease 8A20 Phase 2 [8]
CHF-5074 DMTE071 Alzheimer disease 8A20 Phase 2 [9]
RO-4929097 DMXA6B3 Breast cancer 2C60-2C65 Phase 2 [10]
AL102 DMCTWIB Desmoid tumour 2F7C Phase 2 [11]
⏷ Show the Full List of 20 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gamma-secretase (GS) TT9W8GU APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT02407353) A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on beta-Amyloid (Abeta) Concentrations in Cerebrospinal Fluid (CSF). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.J Pharmacol Exp Ther.2010 Jul;334(1):269-77.
4 The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
5 Clinical pipeline report, company report or official report of Roche (2009).
6 A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50.
7 Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52.
8 Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69(11):1430-40.
9 CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.Br J Pharmacol.2009 Mar;156(6):982-93.
10 Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53.
11 Clinical pipeline report, company report or official report of Ayala Pharmaceuticals.